(Reuters) - Kythera Biopharmaceuticals Inc's injection for "double chin" reduction was backed by U.S. Food and Drug Administration staff, who concluded the drug's benefits outweighed its risks. Kythera's stock jumped 22.5 percent to $48.87 and was one of the top percentage gainers on the Nasdaq on Thursday. via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment